JPWO2020181283A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020181283A5
JPWO2020181283A5 JP2021553031A JP2021553031A JPWO2020181283A5 JP WO2020181283 A5 JPWO2020181283 A5 JP WO2020181283A5 JP 2021553031 A JP2021553031 A JP 2021553031A JP 2021553031 A JP2021553031 A JP 2021553031A JP WO2020181283 A5 JPWO2020181283 A5 JP WO2020181283A5
Authority
JP
Japan
Prior art keywords
amino
pyrimidine
carboxamide
dichlorophenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021553031A
Other languages
English (en)
Japanese (ja)
Other versions
JP7734586B2 (ja
JP2022524759A5 (https=
JP2022524759A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/021726 external-priority patent/WO2020181283A1/en
Publication of JP2022524759A publication Critical patent/JP2022524759A/ja
Publication of JPWO2020181283A5 publication Critical patent/JPWO2020181283A5/ja
Publication of JP2022524759A5 publication Critical patent/JP2022524759A5/ja
Application granted granted Critical
Publication of JP7734586B2 publication Critical patent/JP7734586B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2021553031A 2019-03-07 2020-03-09 Shp2アンタゴニストとしてのカルボキサミド-ピリミジン誘導体 Active JP7734586B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19161323 2019-03-07
EP19161323.1 2019-03-07
US201962879597P 2019-07-29 2019-07-29
US62/879,597 2019-07-29
PCT/US2020/021726 WO2020181283A1 (en) 2019-03-07 2020-03-09 Carboxamide-pyrimidine derivatives as shp2 antagonists

Publications (4)

Publication Number Publication Date
JP2022524759A JP2022524759A (ja) 2022-05-10
JPWO2020181283A5 true JPWO2020181283A5 (https=) 2023-03-15
JP2022524759A5 JP2022524759A5 (https=) 2023-03-15
JP7734586B2 JP7734586B2 (ja) 2025-09-05

Family

ID=70057354

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021553031A Active JP7734586B2 (ja) 2019-03-07 2020-03-09 Shp2アンタゴニストとしてのカルボキサミド-ピリミジン誘導体

Country Status (8)

Country Link
US (2) US11033547B2 (https=)
EP (1) EP3935049A1 (https=)
JP (1) JP7734586B2 (https=)
CN (1) CN113795483B (https=)
AU (1) AU2020232026B2 (https=)
CA (1) CA3127361A1 (https=)
IL (1) IL286077A (https=)
WO (1) WO2020181283A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
CN115916765B (zh) * 2020-07-10 2025-04-18 浙江海正药业股份有限公司 吡啶或嘧啶类衍生物及其制备方法和用途
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
CA3217393A1 (en) 2021-05-05 2022-11-10 Elena S. Koltun Ras inhibitors
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
MX2023012929A (es) * 2021-05-05 2023-11-13 Huyabio Int Llc Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr.
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途
CA3224341A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN114181159B (zh) * 2021-12-28 2024-02-20 南通大学 含2,4,5-三取代嘧啶酰肼衍生物及其制备方法与应用
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN116332908B (zh) * 2023-03-21 2024-07-02 杭州医学院 一种shp2变构抑制剂及其制备方法和应用
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
CN121263418A (zh) 2023-04-07 2026-01-02 锐新医药公司 大环ras抑制剂
KR20260005904A (ko) 2023-04-07 2026-01-12 레볼루션 메디슨즈, 인크. 매크로사이클릭 ras 억제제
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
KR20250172857A (ko) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
TW202502334A (zh) * 2023-05-25 2025-01-16 大陸商正大天晴藥業集團股份有限公司 含有醯胺取代的芳香環的化合物、其藥物組成物及用途
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
CN120842203B (zh) * 2025-09-24 2025-12-05 山东大学 特异性检测shp2的近红外荧光探针的制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125828A (en) 1972-08-04 1978-11-14 Med-El Inc. Method and apparatus for automated classification and analysis of cells
US4207554A (en) 1972-08-04 1980-06-10 Med-El Inc. Method and apparatus for automated classification and analysis of cells
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
CN1255392C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管生成抑制剂的秋水仙醇衍生物
JP6523303B2 (ja) * 2014-01-17 2019-05-29 ノバルティス アーゲー Shp2の活性を阻害するための1−ピリダジン/トリアジン−3−イル−ピペラジン/ピペリジン/ピロリジン誘導体およびその組成物
CN105899493B (zh) 2014-01-17 2019-03-29 诺华股份有限公司 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
UA122786C2 (uk) * 2015-01-30 2021-01-06 Басф Се Гербіцидні фенілпіримідини
ES2824576T3 (es) 2015-06-19 2021-05-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
CN112625028B (zh) 2015-06-19 2024-10-29 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
ES2741746T3 (es) 2015-06-19 2020-02-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
EA202092441A1 (ru) 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
MX383856B (es) 2016-06-14 2025-03-14 Novartis Ag Compuestos y composiciones para inhibir la actividad de shp2.
KR102598895B1 (ko) 2016-07-12 2023-11-07 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
BR112018077111A2 (pt) * 2016-07-26 2019-04-02 Basf Se uso de compostos de pirimidina, compostos de pirimidina, mistura herbicida, composições herbicidas, método para controlar vegetação indesejada e uso das composições
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
TW202500565A (zh) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
US20190343836A1 (en) 2017-01-10 2019-11-14 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
MX2019008695A (es) 2017-01-23 2019-09-11 Revolution Medicines Inc Compuestos biciclicos como inhibidores alostericos de shp2.
MX2019008696A (es) 2017-01-23 2019-09-13 Revolution Medicines Inc Compuestos de piridina como inhibidores de shp2 alostericos.
KR20240026521A (ko) 2017-03-23 2024-02-28 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
WO2019051469A1 (en) 2017-09-11 2019-03-14 Krouzon Pharmaceuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
EP3687997A1 (en) 2017-09-29 2020-08-05 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
NL2019805B1 (en) 2017-10-26 2019-05-06 Swedish Match Lighters Bv A child resistant gas lighter
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
WO2019121373A1 (en) * 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019165073A1 (en) 2018-02-21 2019-08-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
SG11202009245TA (en) 2018-03-21 2020-10-29 Relay Therapeutics Inc Shp2 phosphatase inhibitors and methods of use thereof
US20220033363A1 (en) * 2018-09-19 2022-02-03 Bayer Aktiengesellschaft Herbicidally active substituted phenylpyrimidine hydrazides
TW202028183A (zh) * 2018-10-10 2020-08-01 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
WO2021143823A1 (zh) * 2020-01-16 2021-07-22 浙江海正药业股份有限公司 吡啶或嘧啶类衍生物及其制备方法和用途
CN115916765B (zh) * 2020-07-10 2025-04-18 浙江海正药业股份有限公司 吡啶或嘧啶类衍生物及其制备方法和用途

Similar Documents

Publication Publication Date Title
JPWO2020181283A5 (https=)
JP7734586B2 (ja) Shp2アンタゴニストとしてのカルボキサミド-ピリミジン誘導体
TWI846855B (zh) 作為shp2拮抗劑的嘧啶酮衍生物
CN112513029B (zh) 含氮芳基磷氧化物类衍生物、其制备方法和应用
HRP20231295T1 (hr) Derivati 3-(5-hidroksi-1-oksoizoindolin-2-il)piperidin-2,6-diona i njihova upotreba u liječenju bolesti ovisnih o cinkovom prstu 2 (ikzf2) obitelji ikaros
JP6895439B2 (ja) IRAK4調節因子としてのピラゾロ[1,5a]ピリミジン誘導体
JP5823518B2 (ja) ブルトン型チロシンキナーゼの阻害剤
AU2020276802A1 (en) Inhibitor containing bicyclic derivative, preparation method therefor and use thereof
CA3251001A1 (en) QUINAZOLINE COMPOUNDS AND THEIR USE AS INHIBITORS OF MUTANT KRAS PROTEINS
KR20230033645A (ko) 알로스테릭 egfr 억제제 및 이의 사용 방법
EP4705293A1 (en) Spiro-heterocyclic inhibitors of kras g12c mutant proteins and uses thereof
JP2017505327A5 (https=)
RU2016135637A (ru) 6-гетероарилокси- и 6-арилоксихинолин-2-карбоксамиды и их применение
CN105732637B (zh) 杂芳化合物及其在药物中的应用
KR20240110741A (ko) Shp2 억제제 및 이의 용도
JP2013534902A5 (https=)
JP2016500694A5 (https=)
RU2019100559A (ru) Новые пиримидиновые карбоксамиды в качестве ингибиторов фермента ванин-1
JP2021504380A5 (https=)
IL314895A (en) Pharmaceutical compound
WO2022170043A1 (en) Quinazoline derived compounds as egfr inhibitors and their uses thereof
TW202214596A (zh) 喹唑啉化合物之合成
JP2024009891A (ja) T型カルシウムチャネル阻害剤
WO2018234345A1 (en) PYRAZOLO [1,5A] PYRIMIDINE DERIVATIVES AS MODULATORS OF IRAK4
AU2019363657B2 (en) 5-azaindazole derivatives as adenosine receptor antagonists